Clinical Trials Logo

Pediatric Solid Tumor clinical trials

View clinical trials related to Pediatric Solid Tumor.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05322187 Not yet recruiting - Liver Cancer Clinical Trials

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy

sPLENTY-pc
Start date: April 10, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a single arm, open-label trial studying the combination of PD-1/PD-L1 Inhibitor (e.g.pembrolizumab, Sintilimab,Duvarizumab,Camrelizumab )and lenvatinib given at the recommended dose in pediatric and young adolescent patients((5 year-old<age<14 year-old) with TLCT or refractory hepatoblastoma after chemotherapy.